Our reported findings suggest that the two distinct subpopulations of lung cancer cells have complementary responses to the individual treatments, providing a potential rationale to combine MEK inhibition with immune checkpoint blockade to overcome resistance to the individual therapies, complementing an on-going clinical trial at MD Anderson (ClinicalTrials.gov Identifier: NCT03225664). This evidence concerns the gene MAP2K7 and lung cancer.